Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.

Abstract

Umeclidinium (UMEC) is an inhaled long-acting muscarinic antagonist approved in the US and EU for the once-daily (QD) treatment of chronic obstructive pulmonary disease (COPD); it is not indicated for the treatment of asthma. To fully characterize the dose-response relationship of UMEC in patients with COPD, a pooled analysis of data from two randomized… (More)
DOI: 10.1002/jcph.340

Topics

6 Figures and Tables

Cite this paper

@article{Donohue2014DoseRO, title={Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.}, author={James F. Donohue and Christopher J Kalberg and Palvi Shah and Misba Beerahee and Rashmi C Mehta and Rudy Gunawan and Alison M. Church}, journal={Journal of clinical pharmacology}, year={2014}, volume={54 11}, pages={1214-20} }